Valuation: Tibet Rhodiola Pharmaceutical Holding Co.

Market Cap 1.15TCr 171.36Cr 152.32Cr 141.18Cr 128.45Cr 242.39Cr 16TCr 246.27Cr 1.7TCr 665.36Cr 8.49TCr 643.1Cr 629.41Cr 27TCr P/E 2024
11.3x
P/E 2025 14.6x
Enterprise Value 885.7Cr 132.37Cr 117.66Cr 109.06Cr 99Cr 187.24Cr 13TCr 190.24Cr 1.31TCr 513.97Cr 6.56TCr 496.78Cr 486.2Cr 21TCr EV / Sales 2024
3.4x
EV / Sales 2025 3.72x
Free-Float
39.36%
Yield 2024
5.3%
Yield 2025 4.13%
13/08 Tibet Rhodiola Pharmaceutical Holding Co. Reports Earnings Results for the Half Year Ended June 30, 2026 CI
01/07 Tranche Update on Tibet Rhodiola Pharmaceutical Holding Co.'s Equity Buyback Plan announced on December 18, 2025. CI
08/05 Tibet Rhodiola Pharmaceutical Holding's board elects chairman RE
28/04 Tibet Rhodiola Pharmaceutical Holding Co. Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
01/04 Tranche Update on Tibet Rhodiola Pharmaceutical Holding Co.'s Equity Buyback Plan announced on December 18, 2025. CI
13/03 Tibet Rhodiola Pharmaceutical Logs 11% Decline in 2025 Profit, Revenue Up 6% MT
12/03 Tibet Rhodiola Pharmaceutical Holding Co. Reports Earnings Results for the Full Year Ended December 31, 2025 CI
05/01 Tranche Update on Tibet Rhodiola Pharmaceutical Holding Co.'s Equity Buyback Plan announced on December 18, 2025. CI
18/12 Tibet Rhodiola Pharmaceutical Holding Co. announces an Equity Buyback. CI
18/12 Tibet Rhodiola Pharmaceutical Holding Co. authorizes a Buyback Plan. CI
30/25/30 Tibet Rhodiola Pharmaceutical Holding Co. Reports Earnings Results for the Nine Months Ended September 30, 2025 CI
30/25/30 Ruizheng Gene Co., Ltd. announced that it has received $75 million in funding from China Medical System Holdings Limited, Tibet Rhodiola Pharmaceutical Holding Co. CI
27/25/27 Accuredit Therapeutics Us Limited announced that it expects to receive $75 million in funding from TopRidge Pharma Limited, Cms Medical Venture Investment (HK) Limited, Tibet Rhodiola Pharmaceutical Holding Co., Shenzhen Kangzhe Pharmaceutical Co., Ltd. CI
1 day-1.67%
1 week-2.07%
Current month-0.91%
1 month+0.33%
3 months-10.95%
6 months-14.75%
Current year-15.35%
1 week 35.67
Extreme 35.67
37.12
1 month 35.61
Extreme 35.61
37.47
Current year 34.8
Extreme 34.8
46
1 year 34.8
Extreme 34.8
48.99
3 years 26.95
Extreme 26.953846
57.98
5 years 22.73
Extreme 22.730768
57.98
10 years 13.54
Extreme 13.543846
140.05
Manager TitleAgeSince
Chief Executive Officer 56 20/11/2014
Director of Finance/CFO 48 25/10/2019
Investor Relations Contact 46 -
Director TitleAgeSince
Chairman 70 08/01/2015
Director/Board Member 44 08/01/2015
Director/Board Member 56 08/01/2015
Change 5-day change 1-year change 3-year change Capi.($)
-1.67%-2.07%-26.82%-4.57% 171.36Cr
+0.43%+6.59%+53.41%+103.85% 1,12000Cr
+0.90%-2.25%+33.02%+62.23% 62TCr
+0.71%+3.24%+25.81%+93.86% 50TCr
-0.13%+5.98%+32.91%+50.39% 37TCr
+0.52%+0.24%+73.92%+40.15% 36TCr
-0.95%+4.70%+19.51%+43.00% 29TCr
-1.98%+3.73%-0.86%+13.43% 26TCr
-0.35%+4.25%+46.21%+50.76% 23TCr
-0.75%+3.32%+32.53%+97.21% 19TCr
Average -0.33%+3.03%+28.96%+55.03% 39.43TCr
Weighted average by Cap. +0.13%+3.83%+39.15%+71.40%

Financials

2024 2025
Net sales 280.67Cr 42Cr 37Cr 35Cr 31Cr 59Cr 3.98TCr 60Cr 415.41Cr 162.87Cr 2.08TCr 157.42Cr 154.07Cr 6.62TCr 298.15Cr 45Cr 40Cr 37Cr 33Cr 63Cr 4.23TCr 64Cr 441.29Cr 173.02Cr 2.21TCr 167.23Cr 163.67Cr 7.04TCr
Net income 105.13Cr 16Cr 14Cr 13Cr 12Cr 22Cr 1.49TCr 23Cr 155.6Cr 61Cr 778.13Cr 59Cr 58Cr 2.48TCr 94Cr 14Cr 12Cr 12Cr 11Cr 20Cr 1.33TCr 20Cr 138.82Cr 54Cr 694.23Cr 53Cr 51Cr 2.21TCr
Net Debt -235.14Cr -35Cr -31Cr -29Cr -26Cr -50Cr -3.34TCr -51Cr -348.03Cr -136.45Cr -1.74TCr -131.89Cr -129.08Cr -5.55TCr -260.88Cr -39Cr -35Cr -32Cr -29Cr -55Cr -3.7TCr -56Cr -386.12Cr -151.39Cr -1.93TCr -146.32Cr -143.21Cr -6.16TCr
Projected Income Statement - Annual - Tibet Rhodiola Pharmaceutical Holding Co.
Logo Tibet Rhodiola Pharmaceutical Holding Co.
Tibet Rhodiola Pharmaceutical Holding Co is a China-based company mainly engaged in the business of pharmaceutical manufacturing and pharmaceutical trading. The Company operates two segments, including the Pharmaceutical Manufacturing segment and the Pharmaceutical Trading segment. The Company mainly produces and sells capsules, biological preparations, granules, film coatings, and others. The Company's main products involve cardiovascular and cerebrovascular, hepatobiliary, sprains and contusions, rheumatism, rheumatoid arthritis, colds and other fields. The Company mainly conducts businesses within the domestic market.
Employees
671
Date Price Change Volume
16/26/16 CN¥36.02 -1.67% 32,69,490
15/26/15 CN¥36.63 -0.22% 26,79,024
14/26/14 CN¥36.71 -0.35% 20,67,230
13/26/13 CN¥36.84 +0.03% 21,09,836
12/26/12 CN¥36.83 +0.14% 21,12,730

Annual profits - Rate of surprise

Rate of surprise - EPS - Annual - Tibet Rhodiola Pharmaceutical Holding Co.
  1. Stock Market
  2. Stocks
  3. 600211 Stock